Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Chemotherapy | Heart | HER2 | Herceptin